OasisLMS

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized, progressive, and life-threatening condition often hidden behind common arrhythmias such as atrial fibrillation. As diagnostic tools advance, electrophysiologists are uniquely positioned to play a critical role in the early detection and management of this underdiagnosed disease.

Join the Heart Rhythm Society and BridgeBio for a one-hour interactive webinar exploring the clinical features, diagnostic challenges, and electrophysiologic considerations of ATTR-CM. Expert faculty will share insights into disease pathology, early warning signs, and strategies for timely diagnosis and multidisciplinary management—helping clinicians improve outcomes for patients with structural heart disease and arrhythmias.

Session Highlights:

• What is ATTR-CM and how it differs from other forms of cardiac amyloidosis
• The relationship between ATTR-CM and atrial fibrillation
• Early diagnostic indicators and common misconceptions
• Evidence-based approaches to management and patient care

• Increase aweareness of ATTR-CM.
• Improve diagnostic confidence and competence.
• Enhance clinical decision-making.
• Apply case-based learning.